These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33829639)

  • 1. When Are Treatment Blinding and Treatment Standardization Necessary in Real-World Clinical Trials?
    Watanabe JH; Simon GE; Horberg M; Platt R; Hernandez A; Califf RM
    Clin Pharmacol Ther; 2022 Jan; 111(1):116-121. PubMed ID: 33829639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Series: Pragmatic trials and real world evidence: Paper 6. Outcome measures in the real world.
    Welsing PM; Oude Rengerink K; Collier S; Eckert L; van Smeden M; Ciaglia A; Nachbaur G; Trelle S; Taylor AJ; Egger M; Goetz I;
    J Clin Epidemiol; 2017 Oct; 90():99-107. PubMed ID: 28502810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic?
    Dal-Ré R; Janiaud P; Ioannidis JPA
    BMC Med; 2018 Apr; 16(1):49. PubMed ID: 29615035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments?
    Simon GE; Platt R; Watanabe JH; Bindman AB; John London A; Horberg M; Hernandez A; Califf RM
    Clin Pharmacol Ther; 2022 Jan; 111(1):30-34. PubMed ID: 33895994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Series: Pragmatic trials and real world evidence: Paper 3. Patient selection challenges and consequences.
    Oude Rengerink K; Kalkman S; Collier S; Ciaglia A; Worsley SD; Lightbourne A; Eckert L; Groenwold RHH; Grobbee DE; Irving EA;
    J Clin Epidemiol; 2017 Sep; 89():173-180. PubMed ID: 28502808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethical pitfalls in neonatal comparative effectiveness trials.
    Modi N
    Neonatology; 2014; 105(4):350-1. PubMed ID: 24931328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial.
    Anstrom KJ; Noth I; Flaherty KR; Edwards RH; Albright J; Baucom A; Brooks M; Clark AB; Clausen ES; Durheim MT; Kim DY; Kirchner J; Oldham JM; Snyder LD; Wilson AM; Wisniewski SR; Yow E; Martinez FJ;
    Respir Res; 2020 Mar; 21(1):68. PubMed ID: 32164673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.
    Yiu ZZN; Mason KJ; Barker JNWN; Hampton PJ; McElhone K; Smith CH; Warren RB; Griffiths CEM; Lunt M; Burden AD;
    Br J Dermatol; 2019 Dec; 181(6):1265-1271. PubMed ID: 30822358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Masking in Pragmatic Trials: Who, What, and When to Blind.
    Christian JB; Brouwer ES; Girman CJ; Bennett D; Davis KJ; Dreyer NA
    Ther Innov Regul Sci; 2020 Mar; 54(2):431-436. PubMed ID: 32072597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinding in randomised trials: hiding who got what.
    Schulz KF; Grimes DA
    Lancet; 2002 Feb; 359(9307):696-700. PubMed ID: 11879884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do randomized clinical trials with inadequate blinding report enhanced placebo effects for intervention groups and nocebo effects for placebo groups?
    Feys F; Bekkering GE; Singh K; Devroey D
    Syst Rev; 2014 Feb; 3():14. PubMed ID: 24555576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blinding of outcomes in trials of orthopaedic trauma: an opportunity to enhance the validity of clinical trials.
    Karanicolas PJ; Bhandari M; Taromi B; Akl EA; Bassler D; Alonso-Coello P; Rigau D; Bryant D; Smith SE; Walter SD; Guyatt GH
    J Bone Joint Surg Am; 2008 May; 90(5):1026-33. PubMed ID: 18451395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review.
    Boutron I; Estellat C; Guittet L; Dechartres A; Sackett DL; Hróbjartsson A; Ravaud P
    PLoS Med; 2006 Oct; 3(10):e425. PubMed ID: 17076559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What's the uptake? Pragmatic RCTs may be used to estimate uptake, and thereby population impact of interventions, but better reporting of trial recruitment processes is needed.
    Bell KJL; McCullough A; Del Mar C; Glasziou P
    BMC Med Res Methodol; 2017 Dec; 17(1):174. PubMed ID: 29272994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the design of pragmatic trials: key issues remain.
    Caro JJ; Ishak KJ
    J Comp Eff Res; 2012 Jul; 1(4):319-27. PubMed ID: 24237466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of blinding on treatment effect size estimate in randomized controlled trials of oral health interventions.
    Saltaji H; Armijo-Olivo S; Cummings GG; Amin M; da Costa BR; Flores-Mir C
    BMC Med Res Methodol; 2018 May; 18(1):42. PubMed ID: 29776394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reporting of outcomes in orthopaedic randomized trials: does blinding of outcome assessors matter?
    Poolman RW; Struijs PA; Krips R; Sierevelt IN; Marti RK; Farrokhyar F; Bhandari M
    J Bone Joint Surg Am; 2007 Mar; 89(3):550-8. PubMed ID: 17332104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.